These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 22137318)
1. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Platzbecker U; Santini V; Mufti GJ; Haferlach C; Maciejewski JP; Park S; Solé F; van de Loosdrecht AA; Haase D Leuk Res; 2012 Mar; 36(3):264-70. PubMed ID: 22137318 [TBL] [Abstract][Full Text] [Related]
2. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstöcker M; Rüter B; Sperr WR; Stauder R; Wells DA Leuk Res; 2007 Jun; 31(6):727-36. PubMed ID: 17257673 [TBL] [Abstract][Full Text] [Related]
3. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S; Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and scoring systems in myelodysplastic syndromes. Sanz GF; Sanz MA; Greenberg PL Haematologica; 1998 Apr; 83(4):358-68. PubMed ID: 9592987 [TBL] [Abstract][Full Text] [Related]
5. The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment. Pilo F; Di Tucci AA; Dessalvi P; Caddori A; Angelucci E Eur J Intern Med; 2010 Dec; 21(6):490-5. PubMed ID: 21111932 [TBL] [Abstract][Full Text] [Related]
6. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
7. Advances in supportive care of myelodysplastic syndromes. Gordon MS Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713 [TBL] [Abstract][Full Text] [Related]
8. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Valent P; Horny HP Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651 [TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. Zhang X; Lancet JE; Zhang L Leuk Lymphoma; 2015; 56(11):3022-30. PubMed ID: 25927244 [TBL] [Abstract][Full Text] [Related]
10. Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Greenberg PL; Sanz GF; Sanz MA Forum (Genova); 1999; 9(1):17-31. PubMed ID: 10101208 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the prognosis of patients with myelodysplastic syndromes. Aul C; Giagounidis A; Germing U; Ganser A Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348 [TBL] [Abstract][Full Text] [Related]
12. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Schiffer CA Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963 [TBL] [Abstract][Full Text] [Related]
15. The myelodysplastic syndromes: diagnosis and treatment. Steensma DP; Bennett JM Mayo Clin Proc; 2006 Jan; 81(1):104-30. PubMed ID: 16438486 [TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491 [TBL] [Abstract][Full Text] [Related]
17. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). Fenaux P Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012 [TBL] [Abstract][Full Text] [Related]
18. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826 [TBL] [Abstract][Full Text] [Related]
19. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]